Table 7 The association between IFN-γ and sustained virologic response in HCV subgroups (RVR vs. non-RVR).

From: Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C

IFN-γ (pg/ml)

RVR

non-RVR

SVR

Non-SVR

X2 or Fisher’s

Odds ratio

SVR

Non-SVR

X2 or Fisher’s

Odds ratio

(n = 55)

(n = 1)

p-value

OR (95% C.I)

(n = 18)

(n = 18)

p-value

OR (95% C.I)

IFN-γ 4wk

 <180

48(100.0%)

0(0.0%)

0.143

1.14 (0.88~1.49)

16 (61.5%)

10 (38.5%)

0.06

3.08 (0.86~11.03)

 ≧180

7(87.5%)

1(12.5%)

  

2 (20.0%)

8 (80.0%)

  

IFN-γ 12wk

 <120

40 (100.0%)

0 (0.0%)

0.286

1.07 (0.94~1.21)

13 (68.4%)

6 (31.6%)

0.019

2.33 (1.05~5.16)

 ≧120

15 (93.7%)

1(6.3%)

  

5 (29.4%)

12 (70.6%)

  

IFN-γ EOT

 <40

39 (100.0%)

0 (0.0%)

0.304

1.06 (0.94~1.20)

13 (68.4%)

6 (31.6%)

0.019

2.33 (1.05~5.16)

 ≧40

16 (94.1%)

1 (5.9%)

  

5 (29.4%)

12 (70.6%)

  
  1. p.s. EOT: end of treatment.
Back to article page